- Supply chain disruptions on our production site at the beginning of the year impacting Innohep® sales. Increasing raw material, distribution, energy and interest costs.
- Increased cost-consciousness of payers and patients increasing pricing pressures.
- Cyber security threats.
- Macroeconomic pressures from inflation and interest rates, energy crisis, and stagnating global trade growth.
- Risk of supply disruptions due to unique manufacturing lines and reliance on contract manufacturers.
- Risk of corruption in countries with high perceived levels of corruption and weak law enforcement.
LEO Pharma A/S
Greenhouse gas emissions & sustainability report data
In its 2022 reporting, LEO Pharma A/S disclosed greenhouse gas emissions of 31.1K tonnes CO2e (Scope 1 and 2). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
31.1K tonnes CO2e (Scope 1 and 2)
2022
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2022 | 31.1K tonnes CO2e (Scope 1 and 2) |
| 2021 | 23.1K tCO2e |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- CO2e emissions reduced in line with 2030 target trajectory. Climate targets validated by the Science Based Target initiative.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Deliver positive EBITDA in 2023
📅 Medium-term
- Profitable growth by 2025
🔭 Long-term
- Reduce carbon emissions from own operations by more than 50% from 2019 to 2030
- Ensure 75% of suppliers by emissions have set science-based targets by 2026
🌱 ESG Focus Areas
EnvironmentSocialGovernance